Clinical Trials


An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.

This study has been completed
Boehringer Ingelheim

Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service Identifier

First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: August 2002
History of Changes


To evaluate the potential pharmacokinetic interaction between nevirapine and clarithromycin, and to determine the effects of nevirapine on cytochrome P450 3A4 (CYP3A4) activity in vivo.

Condition Intervention Phase
HIV Infections

Drug : Erythromycin
Drug : Nevirapine
Drug : Clarithromycin
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4.

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Enrollment: 36

Detailed Description:

The study is conducted in two separate groups. Patients in Group I receive clarithromycin orally for 32 days and nevirapine orally for 28 days.
Patients in Group II receive erythromycin intravenously on days 0, 14, 28, and 43 and nevirapine orally for 28 days.



Ages Eligible for Study: 18 Years to 65 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria
Concurrent Medication:
Antiretroviral drugs (i.e., zidovudine, zalcitabine, stavudine, lamivudine, didanosine, indinavir, saquinavir) provided that there has been no change in dosing of the medication > 25% within 4 weeks of study entry.
Patients must have:

  • HIV positive status.
  • CD4 count >= 100 cells/mm3.

  • Prior Medication:
    Patients may be on clarithromycin at study entry.
    Exclusion Criteria
    Co-existing Condition:
    Patients with the following conditions are excluded:
    Malabsorption, severe chronic diarrhea, or inability to maintain adequate oral intake.
    Concurrent Medication:
    Macrolide antibiotics (erythromycin, azithromycin, dirithromycin), azole fungals (ketoconazole, fluconazole, itraconazole), rifampin, rifabutin, phenytoin, terfenadine, astemizole, cisapride, triazolam, midazolam, other non-nucleoside reverse transcriptase inhibitors, antibiotics containing clavulanic acid, and Augmentin.
    Patients with the following prior conditions are excluded:
  • History of drug allergy or known drug hypersensitivity.
  • History of clinically important disease including hepatic, renal, cardiovascular, or gastrointestinal disease.

  • Prior Medication:
  • Investigational drugs or antineoplastic agents within 12 weeks of study entry.
  • Participation in a clinical trial that used ERMBY within one year of study entry.
  • Systemic treatment with drugs known to be potent hepatic enzyme inducers or inhibitors (e.g., oral macrolide antibiotics, azole antifungals, cimetidine, rifampin, rifabutin, and carbamazepine) within 28 days of study entry.
  • Use of protease inhibitors; ritonavir, nelfinavir, indinavir, or non-nucleoside
reverse transcriptase inhibitor compounds e.g., delavirdine) within 4 weeks of study entry.
Prior Treatment:
Radiotherapy within 12 weeks of study entry.
Risk Behavior:
Current history (within the last year) of IVDA, ETOH, or substance abuse.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002194


United States, Florida
South Florida Bioavailability Clinic
Miami, Florida, United States, 331813405

Sponsors and Collaborators

Boehringer Ingelheim
More Information

More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT00002194   History of Changes  
Other Study ID Numbers: 200G  
Study First Received: November 2, 1999  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Antibiotics, Macrolide
Reverse Transcriptase Inhibitors
Cytochrome P-450
Anti-HIV Agents

Additional relevant MeSH terms:
HIV Infections
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Nevirapine processed this data on July 20, 2018
This information is provided by